Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for ARS Pharmaceuticals (SPRY) over the last 3 years, with Q3 2025 value amounting to $88.5 million.

  • ARS Pharmaceuticals' Change in Acquisitions & Divestments rose 4508.2% to $88.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.0 million, marking a year-over-year increase of 1912.35%. This contributed to the annual value of $258.0 million for FY2024, which is 3945.95% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Change in Acquisitions & Divestments is $88.5 million, which was up 4508.2% from $80.0 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $88.5 million for Q3 2025, and its period low was $20.0 million during Q1 2023.
  • For the 3-year period, ARS Pharmaceuticals' Change in Acquisitions & Divestments averaged around $61.4 million, with its median value being $61.0 million (2024).
  • Data for ARS Pharmaceuticals' Change in Acquisitions & Divestments shows a peak YoY increase of 17500.0% (in 2024) and a maximum YoY decrease of 166.67% (in 2024) over the last 5 years.
  • ARS Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $60.0 million in 2023, then increased by 11.67% to $67.0 million in 2024, then surged by 32.09% to $88.5 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $88.5 million for Q3 2025, versus $80.0 million for Q2 2025 and $63.5 million for Q1 2025.